Erlotinib Hydrochloride;Erlotinib HCl NEW

Manufacturer Provide Pharmaceutical Antitumor Erlotinib HCl Powder CAS 183319-69-9 Erlotinib Hydrochloride

Introduction

Product Name: Erlotinib Hydrochloride/Erlotinib HCl

Other Name :ERLOTINIB HCL;ERLOTINIB HCL SALT;ERLOTINIB HCL SALT :TARCEVA;Erlotinib, Hydrochloride Salt;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva;

CAS NO:183319-69-9

Purity: 99%min
Appearance:White crystalline powder

Molecular formula:C22H24ClN3O4

MW:429.9

Melting Pint :223-225°C

Storage :Keep in dark place,Inert atmosphere,Room temperature

Erlotinib hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined as a first-line treatment for locally advanced and metastatic pancreatic cancer.

Application 

Erlotinib hydrochloride is a drug used to treat non-small cell lung cancer.
Erlotinib hydrochloride should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.
Uses Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic
Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).